EPIGENETIC READER INHIBITOR APABETALONE (RVX-208) COUNTERS PROINFLAMMATORY HYPERACTIVATION OF CD14+ MONOCYTES FROM PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE

Sylwia Wasiak,Kim E. Dzobo,Mahnoush Bahjat,Brooke D. Rakai,Yannick Kaiser,Miranda Versloot,Jeffrey Kroon,Stephanie C. Stotz,Laura Tsujikawa,Li Fu,Dean Gilham,Christopher D. Sarsons,Michael O. Sweeney,Jan Johansson,Norman C. W. Wong,Erik S.G. Stroes,Ewelina Kulikowski

EPIGENETIC READER INHIBITOR APABETALONE (RVX-208) COUNTERS PROINFLAMMATORY HYPERACTIVATION OF CD14+ MONOCYTES FROM PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE

2020

Sylwia Wasiak
Kim E. Dzobo
Mahnoush Bahjat
Brooke D. Rakai
Yannick Kaiser
Miranda Versloot
Jeffrey Kroon
Stephanie C. Stotz
Laura Tsujikawa
Li Fu
Dean Gilham
Christopher D. Sarsons
Michael O. Sweeney
Jan Johansson
Norman C. W. Wong
Erik S.G. Stroes
Ewelina Kulikowski

Monocytes and macrophages are key immune cells in the development of cardiovascular disease (CVD). Dysregulated monocyte activation can be reversed by epigenetic therapies. Here we test the effects of apabetalone - a clinical-stage inhibitor of epigenetic bromodomain and extraterminal (BET) readers

Keywords:

Disease
Proinflammatory cytokine
Hyperactivation
RVX 208
Cardiology
Diabetes mellitus
Immunology
Medicine
Type 2 diabetes
CD14
Epigenetics
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations